Status:
COMPLETED
Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Chronic Hepatitis C
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
PHASE2
Brief Summary
This study is being conducted in treatment-naive patients (no previous hepatitis C treatment) to evaluate the safety of valopicitabine (NM283) alone and together with pegylated interferon, a drug appr...
Eligibility Criteria
Inclusion
- Documented clinical history compatible with genotype-1, chronic hepatitis C infection
- Treatment-naive (patient has received no previous therapy for hepatitis C viral infection)
- Other protocol-defined inclusion criteria may apply.
Exclusion
- Patient is pregnant
- Patient is co-infected with hepatitis B or HIV
- Other protocol-defined exclusion criteria may apply.
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00120835
Start Date
July 1 2004
Last Update
June 10 2010
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Bradenton, Florida, United States
2
San Antonio, Texas, United States
3
Santurce, Puerto Rico